Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HKI-272 (Neratinib) in Advanced Non-Small Cell Lung Cancer
NCT00266877Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Dec 2005
- Primary completion
- Jan 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 2, open-label trial of neratinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Puma Biotechnology, Inc. Primary endpoint: Objective Response Rate at 3 years. Started Dec 2005; status: completed.
02
Drugs
neratinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00266877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266877.